EP Patent

EP4450129A2 — Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Assigned to Atea Pharmaceuticals Inc · Expires 2024-10-23 · 2y expired

What this patent protects

Provided is a process for preparing Compound 2 comprising the steps of: (a) dissolving Compound 1 in an organic solvent; (b) adding a sufficient amount of H 2 SO 4 /solvent mixture to the solution of Compound 1 from step (a) to form a hemisulfate salt (Compound 2); (…

USPTO Abstract

Provided is a process for preparing Compound 2 comprising the steps of: (a) dissolving Compound 1 in an organic solvent; (b) adding a sufficient amount of H 2 SO 4 /solvent mixture to the solution of Compound 1 from step (a) to form a hemisulfate salt (Compound 2); (c) stirring the reaction until Compound 2 precipitates; and (d) filtering the Compound 2 precipitate and washing with an organic solvent or a mixture of organic solvents.

Drugs covered by this patent

Patent Metadata

Patent number
EP4450129A2
Jurisdiction
EP
Classification
—
Expires
2024-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Atea Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.